81 results about "Brain ischemia" patented technology

An intracellular calcium concentration increase inhibitor containing as the active ingredient (1) a boron compound represented by the formula (I).

The compound represented by the formula (I) inhibits the increase of the intracellular calcium concentration, and therefore it is deemed to be useful as an agent for the prophylaxis and/or treatment of platelet aggregation, ischemic diseases in hearts and brains, immune deficiency diseases, allorgosis, bronchial asthma, hypertension, cerebrovascular spasm, various renal diseases, pancreatitis, Alzheimer's disease, etc.

The invention discloses a brain ASL, SPECT and MRI image registration and fusion conjoint analysis method and system. Registration is respectively carried out to an ASL image and an MRI image by taking the MRI image as a standard; the ASL image and an SPECT image are fused according to different transparencies; a region to be computed is marked in the faultage of the SPECT image; a closed curve is obtained through carrying out a cubic spline interpolation to the ASL image; the volume and the gray value corresponding to the region to be computed and the gray value of an interesting region body through a circular truncated cone approach mode. According to the invention, the advantages of the ASL image reflected brain blood perfusion, the SPECT image reflected brain blood perfusion and the MRI provided brain structure change are combined; an interesting region is segmented and analyzed through providing interactive calibration operation a doctor and a medical expert; the judgement accuracy of a brain ischemic disease is improved; and iconography instructions are provided for a clinician to formulate a rational therapeutic schedule.

The invention relates to extracting tanshinpropanone from the effective part of the root of red-rooted salvia and preparation thereof and application of medicinal compound from said extracting stuff in preparation of drugs for treatment and prevention for blood shortage disease of heart and brain. Process for tanshinpropanone is as follows, extracting tanshinone type compound by supercritical extracting technique of carbon dioxide, boiling with water and extracting soluble salvianolic acid type and purifying thereof through ethyl acetate, thereafter mixing these two solid powder obtained according to extracting rate and content converting.

A neuroprotective pharmacological method in cerebral ischemic insult comprising administration of L- or DL-threo-DOPS or a pharmaceutically acceptable acid addition salt thereof to a patient. Threo-DOPS directly acts on neurons to exert an effect to protect against neuronal death due to brain ischemia, an antilethal effect, and an anti-edema effect due to excessive polarization of neuronal membrane potential caused by an increase in Na-K-ATPase activity. renaline.

The present invention relates to qi reinforcing qianzheng pills for cerebral thrombosis disease treatment, wherein the qi reinforcing qianzheng pills are a traditional Chinese medicine water paste pill preparation, are prepared from pure traditional Chinese medicines, have characteristics of no toxic and side-effect, short term effect and long term cure, and have functions of platelet aggregation resistance, blood vessel expanding and enhancing, blood glutinousness eliminating, vessel wall elasticity enhancement promoting, brain ischemia improving, brain tissue function adjustment and restoration, blood pressure and blood sugar lowering, immunity increasing and the like. The pills comprise the following 15 traditional Chinese medicines: mongolian milkvetch root, angelica, red peony root, earthworm, szechwan lovage rhizome, peach seed, safflower, sanchi, acanthopanax, giant typhonium tuber, leech, stiff silkworm, scorpion, centipede and salvia miltiorrhiza, wherein the mongolian milkvetch root and the acanthopanax are tonification drugs, and provide functions of qi benefiting, superficial defence strengthening, spleen strengthening, and improvement of qi asthenia, acratia and blood stasis of cerebral thrombosis (qi is the commander of blood, blood is the mother of qi, blood can smoothly circulate if qi runs, and blood stasis can be eliminated if qi runs), and the angelica, the red peony root, the peach seed, the safflower, the sanchi and the acanthopanax are drugs with characteristics of blood circulation activating and blood stasis dissipating, and provide functions of blood circulation improving, blood lipid lowering, blood vessel softening, and blood glutinousness eliminating.

The present invention relates to the field of pharmaceutical chemistry and therapeutics, and particularly relates to an optically active butylphthalide open-ring derivative as shown in the general formula I or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier, preparation methods thereof, pharmaceutical compositions containing the compounds, and medical application thereof, especially application in medicines for prevention and treatment of cardiovascular and cerebrovascular and improvement of heart and brain circulatory disturbance, antiplatelet aggregation medicines, antithrombotic medicines, anti-ischemic medicines, anti-dementia medicines, anti-atherosclerotic medicines, and medicines for anti-diabetes and complications thereof. Pharmacological experimental results show that the compounds have good anti-platelet aggregation activity, anti-thrombotic activity, anti-ischemic activity and neuroprotective effects, and are clinically useful for the preparation of medicines for preventing or treating diseases associated with platelet aggregation.

The present invention relates to a grape seed extract showing neuronal cell protecting activity and the composition comprising the same having neuronal cell protecting activity for preventing and treating degenerative brain disease. The grape seed extract shows potent inhibiting activity of neuronal cell apoptosis occurred in brain ischemia as well as no toxicity, therefore, it can be used as the therapeutics or health food for treating and preventing degenerative brain diseases.

The invention provides a drug composition for treating cardio-cerebrovascular diseases and a preparation method. The drug composition is jointly formed by such active ingredients as 2-10 parts by weight of salvianolic acid B, 0.1-0.5 part by weight of tanshinone IIA, 0.1-0.5 part by weight of ferulic acid, 0.4-2 parts by weight of ligustilide and 2-10 parts by weight of puerarin and the auxiliary added ingredients acceptable in the drugs. Tests show that the drug composition can obviously reduce brain tissue hemorrhagic necrosis caused by brain ischemia reperfusion injury and alleviate injuries of nerve cells and nerve fibers.

The invention relates to application of oligomeric proantho cyanidins in preparing products for preventing, diagnosing, detecting, protecting, treating and studying vascular dementia and directly related diseases thereof, in particular to new application in medicament and health-care products. Experiments prove that oligomeric proantho cyanidins can improve the study memory ability of a heart and brain ischemia-reperfusion mouse and a permanent bilateral common carotid arteries rat, inhibit lipid peroxidation in brains of the heart and brain ischemia-reperfusion mouse and the permanent bilateral common carotid arteries rat, and improve the superoxide dismutase enzyme activity of the heart and brain ischemia-reperfusion mouse and the permanent bilateral common carotid arteries rat. The oligomeric proantho cyanidins have strong action, clear effect, rich resource, simple preparation process, high yield, stable property and safe use, in particular one object with multiple functions and wide application range, and can play roles furthest. Disease rate of dementia rises gradually, after popularization, the application of oligomeric proantho cyanidins can generate significant social benefit and economic benefit in short time.

The invention relates to a preparation method of 24(R)-ocotillol DQ and pharmacal application thereof, belonging to the field of medicines. The preparation method comprises the following steps of: taking 1.0kg of ginsenoside, and adding water for dissolving; adding the dissolved ginsenoside onto a processed macroporous adsorption resin column; eluting with 35-55 percent alcohol until no saponin reacts, and then eluting with 60-90 percent alcohol; after the eluent is evaporated to dryness, adding sodium hydroxide for hydrolyzing, and regulating the pH of a hydrolysate to neutrality; adding the hydrolysate onto a macroporous adsorption resin column AB-8, desalting, and then eluting with 60-90 percent alcohol; and after the eluent is evaporated to dryness, oxidizing and recrystallizing to obtain a product. The invention can be applied to preparing medicaments for preventing and treating brain tissue damages caused by local and global brain ischemia, treating transient ischemic attacks, cerebral thrombosis and cerebral infarctions.

The invention relates to a high-purity polyphyllin VI preparation method and an application, and belongs to the field of Chinese herbal medicine extraction and separation. The method includes the specific steps: roughly crushing Chinese paris rhizome or wake robin medicinal materials, performing ethanol extraction; sequentially performing macroporous adsorption resin, silica gel and reverse-phase material column chromatography on extracting solution; taking ethyl acetate, ethanol and water as eluting agents and filtering, washing and drying sedimentation portions after recovering solvents by eluent to obtain high-purity polyphyllin VI. The method has the advantages that the operation steps are easily repeated, conditions are easily controlled and amplified, the solvents are low in toxicity and easy to recover, and the like. The obtained polyphyllin VI is basically free from organic solvent residues, and the purity of the polyphyllin VI reaches 98% or more. After pharmacodynamical research of the influence of mouse normal pressure hypoxia tolerance, mouse brain ischemia caused by common carotid artery ligation, rat myocardium injury caused by ischemia reperfusion, myocardial infarction caused by rat isolated heart myocardial ischemia and the like, the polyphyllin VI serving as a final product is good in effect and can be used for developing products for treating cardiovascular and cerebrovascular diseases.

One aspect of the present invention relates to amines. A second aspect of the present invention relates to the use of the amines as inhibitors of a mammalian anandamide transporter. The compounds of the present invention will also find use in the treatment of numerous ailments, conditions and diseases which afflict mammals, including but not limited to asthma, neuropathic pain, persistent pain, inflammatory pain, hyperactivity, hypertension, brain ischemia, Parkinson's disease, spasticity, Tourette's syndrome, schizophrenia, hemorrhagic shock, septic shock, cardiac shock, migrane, Horton's headache, multiple sclerosis, anorexia, AIDS wasting syndrome, organ rejection, autoimmune diseases, allergy, arthritis, Crohn's disease, malignant gliomas, neurodegenerative diseases, Huntington's chorea, glaucoma, nausea, anxiety, psychosis, attention deficit hyperactivity disorder, premature ejaculation, and stroke. Another aspect of the present invention relates to combinatorial libraries of amines, and methods for preparing the libraries.

The invention discloses bear gall powder capable of inhibiting thrombosis and platelet aggregation and preventing cerebral ischemia and application. The bear gall powder can be used for adjusting blood fat, reducing total cholesterol, preventing cardiovascular and cerebrovascular diseases and preventing atherosclerosis; the invention discloses a preparation method of the bear gall powder and the bear gall powder obtained through the method. In a bear gall powder preparation process, materials are subjected to ice crystallization, then freeze drying is conducted, and the obtained freeze dried bear gall powder can be called ice crystal state bear gall powder or can be called ice crystal bear gall powder; especially, the bear gall powder which can be called Senbao bear gall powder does not contain any auxiliaries or chemical additives; especially, the ice crystal state bear gall powder not only can more effectively adjust the blood fat and reduce the total cholesterol, but also can be more effectively used for preventing the cardiovascular and cerebrovascular diseases, preventing atherosclerosis and preventing and treating solid tumors and hematological system tumors, and more especially, the ice crystal state bear gall powder can be effectively used for inhibiting thrombosis, inhibiting platelet aggregation and preventing cerebral ischemia and ischemic encephalopathy.

Disclosed is a composition for protecting nerve cells, promoting nerve cell growth and regenerating nerve cells comprising berberine, derivatives thereof or pharmaceutically acceptable salts thereof. The composition has protective effects against apoptosis of neuronal stem cells and differentiated neuronal stem cells, an effect of inducing the regeneration of nerve cells, a regenerative effect on neurites, a neuroregenerative effect on central nerves and peripheral nerves, a reformation effect on neuromuscular junctions, and a protective effect against apoptosis of nerve cells and a neuroregenerative effect in animals suffering from dementia and brain ischemia. Therefore, the composition can be used as a therapeutic agent for the prevention and treatment of neurodegenerative diseases, ischemic nervous diseases or nerve injuries, and for the improvement of learning capability.

A method and an apparatus for determining brain ischemia features on the basis of magnetic resonance diffusion-weighted imaging (DWI), so as to provide an objective basis for determining whether to apply a thrombolytic therapy to an acute brain ischemia patient. The method comprises: determining a brain ischemia area of a to-be-detected patient according to magnetic resonance DWI of the to-be-detected patient, the brain ischemia area comprising a core area and a transition area; determining, according to DWI values of the core area and the transition area, an apparent diffusion coefficient (ADC) feature parameter ADC r in an area with a high DWI value in the magnetic resonance DWI; and determining, according to the ADC feature parameter ADC r, whether an ADC value in the area with a high DWI value is mismatched with the area with a high DWI value. With this method, it is more scientific and objective to make a decision whether to apply a thrombolytic therapy to a brain ischemia patient, thereby improving the cure rate of the brain ischemia patient.

The invention relates to a functional food preparation for brain development and eye protection. The functional food preparation is prepared from the following components: phosphatidylserine, DHA algal oil powder, lutein esters, zinc gluconate and bilberry fruit powder; the functional food preparation for brain development and eye protection can be prepared into one of tablets, capsules or powder solid beverages. The invention further relates to a preparation method of the functional food preparation for brain development and eye protection. The preparation method comprises the steps of granulating, sieving and drying. The functional food preparation for brain development and eye protection has the obvious effects of resisting ischemia and reducing brain ischemic injuries, and a step-down memory function caused by reperfusion injuries of brain ischemia is obviously improved. According to the preparation prepared by using the preparation method, cognitive learning and memory of young students, especially the students for senior high school entrance examinations and college entrance examinations, can be effectively increased, the pressure is relieved, and eyes are protected; the working pressure of white collar workers who face electronic screens all day is relieved, and eyes are protected; alzheimer diseases and eye macular degeneration of old people are prevented and relieved.

The invention relates to an oral solid medicine composition for nervous system diseases. The composition is a tablet and comprises an active component, lactose anhydrous, a disintegrating agent and an adhesive. The medicine composition can be used for a cerebrovascular disease, used for improving brain metabolism and mental symptoms, activating respiratory activity of brain mitochondria, improving brain energy metabolism of brain ischemia, increasing a utilization ratio of glucose in a brain, allowing adenosine triphosphate produced in the brain to be increased, preventing brain mitochondrion from generating peroxidized lipin, and inhibiting a membrane obstruction due to lipid peroxidation of a brain mitochondrial membrane, used for brain function injures caused by the chronic cerebrovascular disease, brain trauma and the like, and used for improving mental and behavioral disorders such as a subjective symptom, a language disorder, anxiety, depression, hypomnesia and brain power declining, promoting brain power, activating a brain mitochondrion function, improving the brain energy metabolism and a brain function, improving emotion depression, low consciousness, an affective disorder, a language disorder and the like that are caused by a cerebral infarction sequela, a cerebral hemorrhage sequela and cerebral arteriosclerosis, improving brain metabolism, and protecting cranial neural cells.

The present invention provides a method of aiding the differential diagnosis of haemorrhagic stroke, ischemic stroke and a transient ischemic attack in a patient who has suffered or is suffering a stroke. The method comprises: (i) determining the concentration of the biomarkers VCAM-1, GFAP and CRP in an ex vivo sample obtained from the patient; and (ii) establishing the statistical significance of the concentration of the biomarkers. Optionally, the method further comprises steps of (iii) determining the concentration of the biomarkers IL-6 and sTNFR1 in an ex vivo sample obtained from the patient; (iv) determining the gender of the patient; and (v) establishing the statistical significance of the concentration of the five biomarkers, in conjunction with the patient's gender. The present invention also provides substrates comprising probes for VCAM-1, GFAP and CRP for use in a method for aiding the differential diagnosis of stroke.